RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Molecular and serologic markers of acute dengue infection in naive and flavivirus-vaccinated travelers.

A total of 520 European travelers with suspected dengue fever were examined, and acute dengue virus infection was confirmed in 127 of them. Molecular and serological tests for dengue diagnosis, according to their usefulness in the different stages of the disease, were performed. The accuracy of the IgM/IgG ratio and the IgG avidity index was confirmed during the early phase of the illness to discriminate the serologic status (primary versus secondary immune response) of patients who were either naive or previously vaccinated against other flaviviruses. Virologic markers of secondary infection were detected in 11.8% of nonvaccinated infected patients and in 92.6% of yellow fever vaccinated patients. The proper use of these simple methodologies could help in the identification of patients affected with secondary infection, who may be at a higher risk of developing a hemorrhagic disorder.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app